

### **AMENDMENTS TO THE SPECIFICATION**

Further to the Examiner's request, section headings are being added to the specification and other non-substantive changes are being made. All paragraph numbers herein reference the published version of this application US 2006/0100145 A1. These changes are not believed to introduce new matter.

Following the title but prior to paragraph [0001] please insert the following paragraph:

[0000] Background

Please replace paragraph [0003] with the following paragraph which has been marked up to show the changes made:

[0003] Brief Description of the Figures

Please replace paragraph [0021] with the following paragraph which has been marked up to show the changes made:

[0021] illustrates in parts 9A and 9B expression Expression of GORI-28 and TIG2 in various cell types. The abbreviations used in the figure are described in Example 12.

Please replace paragraph [0023] with the following paragraph which has been marked up to show the changes made:

[0023] illustrates in parts 10A and 10B expression Expression of GORI-28 and TIG2 in skin samples from patients with skin diseases. As described in Example 13, the following abbreviations are used in the figure: C is a control (no skin disease); Pso represents patients suffering from psoriasis; AD represents patients suffering from atopic dermatitis.

Following paragraph [0024] but prior to paragraph [0025] please insert the following paragraph:

[0024.1] Detailed Description